Drug Prices

Blog

Read part 1 of a 3 part series on drug pricing

Conspiracies Aside, Drug Company Profits Are Average

Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Commentary

A Promising New AIDS Drug Highlights The Dangers Of Price Controls

The U.S. Food and Drug Administration approved a shot last month that effectively prevents HIV. At-risk people simply need to receive the injection every six months. The new drug, called lenacapavir, comes almost exactly 44 years after the first case of AIDS was reported by what’s now known as the ...
Commentary

Price Controls On Doctors Are Costing Patients Dearly

Just like the December 2024 continuing resolution, the current budget reconciliation bill fails to address the problem of Medicare reimbursing physicians at below market rates. Without a fix, the inevitable consequences will be worsening doctor shortages, declining healthcare quality, higher overall healthcare spending, and the accelerated loss of independent practices. ...
Commentary

A Real and Present Threat to Alzheimer’s Patients

It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments. Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging ...
Blog

The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe

Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
Drug Importation

Listen to Sally Pipes on “Free the Economy” podcast

Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Commentary

Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Blog

Don’t Take Cutting-Edge Drugs for Granted

It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Blog

Read part 1 of a 3 part series on drug pricing

Conspiracies Aside, Drug Company Profits Are Average

Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Commentary

A Promising New AIDS Drug Highlights The Dangers Of Price Controls

The U.S. Food and Drug Administration approved a shot last month that effectively prevents HIV. At-risk people simply need to receive the injection every six months. The new drug, called lenacapavir, comes almost exactly 44 years after the first case of AIDS was reported by what’s now known as the ...
Commentary

Price Controls On Doctors Are Costing Patients Dearly

Just like the December 2024 continuing resolution, the current budget reconciliation bill fails to address the problem of Medicare reimbursing physicians at below market rates. Without a fix, the inevitable consequences will be worsening doctor shortages, declining healthcare quality, higher overall healthcare spending, and the accelerated loss of independent practices. ...
Commentary

A Real and Present Threat to Alzheimer’s Patients

It’s a quintessential government outcome. A program intended to increase access to promising medical innovations is actually preventing Medicare beneficiaries from receiving FDA-approved treatments. Medicare’s “coverage with evidence development” (CED) was never authorized by Congress. Instead, the Centers for Medicare & Medicaid Services created the program in 2005 by leveraging ...
Blog

The 340B Discounts Hospitals Receive Will Often Exceed Total Drug Prices in Europe

Table 1: PBM Fees and Rebates Can Exceed International Prescription Medicine Prices by As Much As 900% I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used brand medicines far exceed the total prices of those medicines in eight OECD countries (see Table 1). For example, ...
Drug Importation

Listen to Sally Pipes on “Free the Economy” podcast

Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Commentary

Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Blog

Don’t Take Cutting-Edge Drugs for Granted

It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Scroll to Top